Trial Profile
A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 24 Jan 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2022.
- 31 Aug 2021 Planned End Date changed from 28 Apr 2019 to 30 Dec 2021.